Elmira M. Zulkarneeva
Research Subjects
Elmira M. Zulkarneeva has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Indira V. Sakhautdinova
Bashkir State Medical University, Ministry of Health of the Russian Federation
2 shared publications - Anna Malyshkina
Institute of Physiology, University of Duisburg-Essen, University Hospital Essen, Essen, Germany.
1 shared publication E.V. Tikhomirova
1 shared publication- Elena Nikolaevna Kravchenko
Omsk State Medical University
1 shared publication - Elena V. Tikhomirova
Moscow University “Synergy
1 shared publication - I. V. Sakhautdinova
Bashkir State Medical University, Ufa, Russian Federation
1 shared publication
Latest Publications
- Open Access
- 14 July 2023
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 25 (2) , 153-157
Symptoms and clinic of postmenopausal vulvovaginal atrophy in different stages of postmenopause: A cross sectional study
Hypoestrogenism associated with menopause has a strong negative effect on the condition of the vagina and urinary tract, and often leads to the development of genitourinary menopausal syndrome, significantly disrupting the quality of life of women. Menopausal vulvovaginal atrophy is diagnosed in 36 to 90% of peri- and postmenopausal women. In recent years, it has been revealed that this condition is also present in 19% of women aged 4045 years during premenopause. Aim. The aim of the study was to study the relationship between the dynamics of the severity of symptoms and their impact on the quality of life of women, and the clinical manifestations of postmenopausal atrophic vaginitis, depending on the stage of postmenopause. Results. Patients in the early postmenopausal period had a vaginal health index consistent with moderate atrophy. Throughout the postmenopausal period studied, clinical manifestations of vaginal atrophy progressed, and in the late menopausal period, the vaginal health index was consistent with severe atrophy. Conclusion. In our opinion the therapy of vulvovaginal atrophy should begin with the period of early menopause. At this time, women are most interested in treatment, as their quality of life suffers significantly due to the newly appeared extremely unpleasant sensations. At the same time, minor atrophic changes in the tissues of the vagina and vulva are easier to treat.
- 14 July 2023
- Published by Consilium Medicum in GYNECOLOGY
- Vol. 25 (2) , 153-157
Open AccessSymptoms and clinic of postmenopausal vulvovaginal atrophy in different stages of postmenopause: A cross sectional study
Hypoestrogenism associated with menopause has a strong negative effect on the condition of the vagina and urinary tract, and often leads to the development of genitourinary menopausal syndrome, significantly disrupting the quality of life of women. Menopausal vulvovaginal atrophy is diagnosed in 36 to 90% of peri- and postmenopausal women. In recent years, it has been revealed that this condition is also present in 19% of women aged 4045 years during premenopause. Aim. The aim of the study was to study the relationship between the dynamics of the severity of symptoms and their impact on the quality of life of women, and the clinical manifestations of postmenopausal atrophic vaginitis, depending on the stage of postmenopause. Results. Patients in the early postmenopausal period had a vaginal health index consistent with moderate atrophy. Throughout the postmenopausal period studied, clinical manifestations of vaginal atrophy progressed, and in the late menopausal period, the vaginal health index was consistent with severe atrophy. Conclusion. In our opinion the therapy of vulvovaginal atrophy should begin with the period of early menopause. At this time, women are most interested in treatment, as their quality of life suffers significantly due to the newly appeared extremely unpleasant sensations. At the same time, minor atrophic changes in the tissues of the vagina and vulva are easier to treat.
- 1 January 2023
- Published by Dynasty Publishing House in Voprosy Ginekologii, Akušerstva i Perinatologii
- Vol. 22 (3)
Treatment and prevention of miscarriage in real clinical practice. A prospective multicenter study
Objective. To evaluate the efficacy and safety of micronized progesterone as part of the most common treatment regimens for preventing miscarriage, as well as patient satisfaction and adherence; to examine the overall clinical response to therapy and to determine the rate of pregnancy prolongation until fetal viability is reached based on physician assessments. Patients and methods. Data were collected from a sample of 300 patients in their first trimester of pregnancy who were admitted to hospital for inpatient treatment (with bleeding and/or pain) and to whom as part of pharmacotherapy regimens Prajisan® was prescribed at a daily dose of 400 mg (200 mg twice daily, intravaginal route; as indicated and according to instructions for medical use). All the procedures performed were routine, which defined the non-interventional nature of this study. Patient medical records and characteristics of their current pregnancy, including the use of medications, the presence of complications, length of stay, and adverse events that occurred during the entire period of observation and treatment, were assessed. Moreover, the survey contained additional, specially designed questionnaires to assess the patient’s condition in dynamics, the physician’s satisfaction with the therapeutic effect, and the patient’s satisfaction with the treatment used (Likert scale). The primary endpoint was the prolongation of pregnancy until hospital discharge; the secondary endpoint was the prolongation of pregnancy until potential fetal viability (up to 22 weeks and 0 days). Mathematical and statistical data processing was performed using standard software packages Statistica (v7.0) and SPSS Statistics (v23.0). Results. The efficacy of combination therapy (achievement of the primary endpoint), which included micronized progesterone (Prajisan® 200 mg intravaginally twice daily), was 96.84%. The therapy was not associated with adverse events in 100% of cases. Physician and patient satisfaction with the convenience of use (according to the mean Likert score) did not differ significantly and was 4.21 ± 0.7 and 4.07 ± 0.8, respectively. Physician satisfaction with the clinical response to treatment was significantly higher than patient satisfaction with the convenience of use (mean Likert score was 4.39 ± 0.5 and 4.07 ± 0.8, respectively). The secondary endpoint was reached in 100% of the patients discharged from hospital with progression of pregnancy. No adverse events were recorded. Conclusion. The findings of this prospective multicenter study obtained in different medical institutions in nine major cities of Russia (including megacities) allow us to conclude about the positive experience with the use of Prajisan® and to recommend it for pregnancy prolongation in the routine practice of Russian obstetricians and gynecologists. Key words: early pregnancy loss, miscarriage, risk factors, prevention, micronized progesterone
- 1 January 2023
- Published by Dynasty Publishing House in Voprosy Ginekologii, Akušerstva i Perinatologii
- Vol. 22 (3)
Treatment and prevention of miscarriage in real clinical practice. A prospective multicenter study
Objective. To evaluate the efficacy and safety of micronized progesterone as part of the most common treatment regimens for preventing miscarriage, as well as patient satisfaction and adherence; to examine the overall clinical response to therapy and to determine the rate of pregnancy prolongation until fetal viability is reached based on physician assessments. Patients and methods. Data were collected from a sample of 300 patients in their first trimester of pregnancy who were admitted to hospital for inpatient treatment (with bleeding and/or pain) and to whom as part of pharmacotherapy regimens Prajisan® was prescribed at a daily dose of 400 mg (200 mg twice daily, intravaginal route; as indicated and according to instructions for medical use). All the procedures performed were routine, which defined the non-interventional nature of this study. Patient medical records and characteristics of their current pregnancy, including the use of medications, the presence of complications, length of stay, and adverse events that occurred during the entire period of observation and treatment, were assessed. Moreover, the survey contained additional, specially designed questionnaires to assess the patient’s condition in dynamics, the physician’s satisfaction with the therapeutic effect, and the patient’s satisfaction with the treatment used (Likert scale). The primary endpoint was the prolongation of pregnancy until hospital discharge; the secondary endpoint was the prolongation of pregnancy until potential fetal viability (up to 22 weeks and 0 days). Mathematical and statistical data processing was performed using standard software packages Statistica (v7.0) and SPSS Statistics (v23.0). Results. The efficacy of combination therapy (achievement of the primary endpoint), which included micronized progesterone (Prajisan® 200 mg intravaginally twice daily), was 96.84%. The therapy was not associated with adverse events in 100% of cases. Physician and patient satisfaction with the convenience of use (according to the mean Likert score) did not differ significantly and was 4.21 ± 0.7 and 4.07 ± 0.8, respectively. Physician satisfaction with the clinical response to treatment was significantly higher than patient satisfaction with the convenience of use (mean Likert score was 4.39 ± 0.5 and 4.07 ± 0.8, respectively). The secondary endpoint was reached in 100% of the patients discharged from hospital with progression of pregnancy. No adverse events were recorded. Conclusion. The findings of this prospective multicenter study obtained in different medical institutions in nine major cities of Russia (including megacities) allow us to conclude about the positive experience with the use of Prajisan® and to recommend it for pregnancy prolongation in the routine practice of Russian obstetricians and gynecologists. Key words: early pregnancy loss, miscarriage, risk factors, prevention, micronized progesterone
- Open Access
- 1 January 2021
- Published by LLC Russian Medical Journal in Russian Journal of Woman and Child Health
- Vol. 4 (3) , 192-200
Efficacy of normalization of vaginal microbiota after antimicrobial treatment for bacterial vaginosis and bacterial vaginosis in pregnant women (results of the multicenter prospective non-interventional comparative study)
- 1 January 2021
- Published by LLC Russian Medical Journal in Russian Journal of Woman and Child Health
- Vol. 4 (3) , 192-200
Open AccessEfficacy of normalization of vaginal microbiota after antimicrobial treatment for bacterial vaginosis and bacterial vaginosis in pregnant women (results of the multicenter prospective non-interventional comparative study)